Inve India ▾

Jubilant Ingrevia share price & results

Jubilant Ingrevia Limited· Chemicals· Commodities

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Specialty chemicals & CDMO maker serving pharma, agro, nutrition, cosmetics and semiconductor customers globally.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue1,394 ₹ crore+24.4% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin15.0 %+3.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit111 ₹ crore+60.9% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity10.82 %+0.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin5.36 %+1.6 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)15.40 %+4.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

6 of 9 judged targets kept · 11 open · verdicts reflect calls analysed to Q1 FY27.

Jubilant Ingrevia Limited management guidance track record on Inve: 20 targets tracked across analysed earnings calls (6 achieved, 3 missed, 11 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue from $300mn Agro CDMO contractstart getting benefit of revenues... starting Q4 of FY26
Call transcript, Q3 FY25 · 28 Feb 2025		Q3 FY25Q1 FY27:Management revealed that full volumes for the contract were not served in Q1 due to a temporary pause requested by the innovator amid raw material price hikes. The original promise to 'start' in Q4 FY26 remains achieved.
Call transcript, Q1 FY27 · 27 Jul 2026		Achieved
ROCE17-20% in the coming years
Call transcript, Q3 FY25 · 28 Feb 2025		Q3 FY25Q1 FY27:No update was provided on the overall company ROCE metric, continuing a pattern of ghosting on this specific target.
Call transcript, Q1 FY27 · 27 Jul 2026		Ghosted
Nutrition Steady State EBITDA Margin16% to 18% in steady state
Call transcript, Q4 FY25 · 13 May 2025		Q4 FY25Q1 FY27:Margin improved to 15% from 14% in the previous quarter. While showing positive momentum, it remains below the 16-18% target range.
Call transcript, Q1 FY27 · 27 Jul 2026		At Risk

Source: Inve Guidance Tracker for Jubilant Ingrevia Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Jubilant Ingrevia Limited's 20 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹606 +0.68% · +₹4.1

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −10.6% 1Y

₹550₹600₹650₹700₹750Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 27 Oct 2025Q3 FY26 — 5 Feb 2026Q4 FY26 — 26 May 2026Q1 FY27 — 27 Jul 2026

1Y: ₹677.7 on 24 Oct 2025 → ₹606. High ₹763.8 (21 Jul 2026), low ₹541.3 (9 Mar 2026).

Previous close
₹601.9
Market cap
₹10.1k Cr
52-week range
₹541.3 – ₹763.8
One year
−10.52%
Price to earnings (TTM to Sept 2026)
28.06×
Return on equity (TTM to Sept 2026)
10.82%

Overview

Symbol
NSE:JUBLINGREA
Sector
Chemicals
Industry
Commodities
Exchange
NSE
Currency
INR

What Jubilant Ingrevia Limited does

Based on the company's own presentations, annual report and earnings calls.

Jubilant Ingrevia Limited manufactures specialty chemicals, Custom Development & Manufacturing (CDMO) solutions and nutrition ingredients for pharmaceutical, agrochemical, personal-care, semiconductor and industrial customers. It operates through three segments built on a base of 35+ proprietary chemistries: Specialty Chemicals (Pyridine & Picolines, fine/diketene derivatives, CDMO for agro/pharma/semicon), Nutrition & Health Solutions (animal and human nutrition, Vitamin B3, Choline, premixes) and Chemical Intermediates (Acetic Anhydride, Ethyl Acetate and related derivatives). It holds global leadership positions in several of these product lines and earns revenue by supplying customers in India as well as export markets including the US, Europe, Japan, the Middle East and South East Asia.

Segments

  • Specialty Chemicals
  • Nutrition & Health Solutions
  • Chemical Intermediates
Manufacturing facilities
5 facilities with 50+ plants in India
Employees
2,300+
R&D centres
3 centres employing 150+ scientists
Product portfolio
130+ products
Legacy in chemicals industry
45+ years
Global market position
Top global player in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride and Vitamin-B3
Founded 2019Headquarters Noida, Uttar Pradesh, India Company website

How the price took the results

close before → close after

Q1 FY27
+2.6%
27 Jul
Q4 FY26
−4.7%
26 May
Q3 FY26
−4.0%
5 Feb
Q2 FY26
−0.1%
27 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Jubilant Ingrevia Limited

Free account: one company. Everything above stays public.

Write why you follow Jubilant Ingrevia Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Chemicals companies

All Chemicals companies → · Chemicals earnings growth →

Learn to analyse Jubilant Ingrevia Limited

Guides on how to read this kind of business and the numbers that matter.